(Bloomberg) -- Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste. The deal raised around £2.5 billion ($3.1 billion ...

Pfizer PFE-0.49%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN-0.95%decrease; red down pointing triangle for 2.50 billion ...

In the latest trading session, Pfizer (PFE) closed at $26.41, marking a -1.46% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.12%. At the same time ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Pfizer saved $4 billion, plans $1.5 billion more in margin improvements, and issued $7 billion in dividends in nine months. Acquisitions are projected to offset $17 billion-18 billion in revenue ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...

Jan 15 (Reuters) - Pfizer (PFE.N), opens new tab will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon (HLN.L), opens new tab, lowering its stake in the British consumer healthcare ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera Therapeutics outlining their plans in the space moving forward. At the 2025 ...

Here’s what you need to know heading into Day Two. Pfizer announced plans to go “all in” on its experimental obesity drug danuglipron. Calling it “danu” for short, CEO Albert Bourla said late-stage ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of $33.00. Discover outperforming stocks and invest ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues in 2025, says CEO Albert Bourla. The company achieved its 2024 goal of ...